Seelos Therapeutics Doses the First Amyotrophic Lateral Sclerosis (ALS) Patient with SLS-005 in an Expanded Access Program
- The Expanded Access Program is funded by a grant from the National Institute of Neurological Disorders and Stroke under the Accelerating Access to Critical Therapies for ALS for ALS patients who... | April 4, 2023